FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310673887> ?p ?o ?g. }

• W4310673887 endingPage "2758" @default.
• W4310673887 startingPage "2746" @default.
• W4310673887 abstract "Background & AimsGrowing evidence supports a role of gut-derived metabolites in nonalcoholic fatty liver disease (NAFLD), but the relation of endotoxin levels with gut permeability and NAFLD stage remains unclear. This systematic review with meta-analysis aims to provide further insights.MethodsPubMed, Embase, and Cochrane Library were searched for studies published until January 2022 assessing blood endotoxins in patients with NAFLD. Meta-analyses and univariate/multivariate meta-regression, as well as correlation analyses, were performed for endotoxin values and potential relationships to disease stage, age, sex, parameters of systemic inflammation, and metabolic syndrome, as well as liver function and histology.ResultsForty-three studies were included, of which 34 were used for meta-analyses. Blood endotoxin levels were higher in patients with simple steatosis vs liver-healthy controls (standardized mean difference, 0.86; 95% confidence interval, 0.62–1.11) as well as in patients with nonalcoholic steatohepatitis vs patients with nonalcoholic fatty liver/non-nonalcoholic steatohepatitis (standardized mean difference, 0.81; 95% confidence interval, 0.27–1.35; P = .0078). Consistently, higher endotoxin levels were observed in patients with more advanced histopathological gradings of liver steatosis and fibrosis. An increase of blood endotoxin levels was partially attributed to a body mass index rise in patients with NAFLD compared with controls. Nevertheless, significant increases of blood endotoxin levels in NAFLD retained after compensation for differences in body mass index, metabolic condition, or liver enzymes. Increases in blood endotoxin levels were associated with increases in C-reactive protein concentrations, and in most cases, paralleled a rise in markers for intestinal permeability.ConclusionOur results support blood endotoxin levels as relevant diagnostic biomarker for NAFLD, both for disease detection as well as staging during disease progression, and might serve as surrogate marker of enhanced intestinal permeability in NAFLD.Registration number in Prospero: CRD42022311166 Growing evidence supports a role of gut-derived metabolites in nonalcoholic fatty liver disease (NAFLD), but the relation of endotoxin levels with gut permeability and NAFLD stage remains unclear. This systematic review with meta-analysis aims to provide further insights. PubMed, Embase, and Cochrane Library were searched for studies published until January 2022 assessing blood endotoxins in patients with NAFLD. Meta-analyses and univariate/multivariate meta-regression, as well as correlation analyses, were performed for endotoxin values and potential relationships to disease stage, age, sex, parameters of systemic inflammation, and metabolic syndrome, as well as liver function and histology. Forty-three studies were included, of which 34 were used for meta-analyses. Blood endotoxin levels were higher in patients with simple steatosis vs liver-healthy controls (standardized mean difference, 0.86; 95% confidence interval, 0.62–1.11) as well as in patients with nonalcoholic steatohepatitis vs patients with nonalcoholic fatty liver/non-nonalcoholic steatohepatitis (standardized mean difference, 0.81; 95% confidence interval, 0.27–1.35; P = .0078). Consistently, higher endotoxin levels were observed in patients with more advanced histopathological gradings of liver steatosis and fibrosis. An increase of blood endotoxin levels was partially attributed to a body mass index rise in patients with NAFLD compared with controls. Nevertheless, significant increases of blood endotoxin levels in NAFLD retained after compensation for differences in body mass index, metabolic condition, or liver enzymes. Increases in blood endotoxin levels were associated with increases in C-reactive protein concentrations, and in most cases, paralleled a rise in markers for intestinal permeability. Our results support blood endotoxin levels as relevant diagnostic biomarker for NAFLD, both for disease detection as well as staging during disease progression, and might serve as surrogate marker of enhanced intestinal permeability in NAFLD." @default.
• W4310673887 created "2022-12-15" @default.
• W4310673887 creator A5019403269 @default.
• W4310673887 creator A5029282864 @default.
• W4310673887 creator A5049602464 @default.
• W4310673887 creator A5050663021 @default.
• W4310673887 creator A5054615432 @default.
• W4310673887 creator A5070102732 @default.
• W4310673887 creator A5070183360 @default.
• W4310673887 creator A5082473440 @default.
• W4310673887 creator A5088567403 @default.
• W4310673887 creator A5089140297 @default.
• W4310673887 creator A5089562986 @default.
• W4310673887 date "2023-10-01" @default.
• W4310673887 modified "2023-10-03" @default.
• W4310673887 title "Blood Endotoxin Levels as Biomarker of Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis" @default.
• W4310673887 cites W1488452840 @default.
• W4310673887 cites W1853350807 @default.
• W4310673887 cites W1892559326 @default.
• W4310673887 cites W1940172037 @default.
• W4310673887 cites W1978501831 @default.
• W4310673887 cites W1997273123 @default.
• W4310673887 cites W2006914906 @default.
• W4310673887 cites W2009452166 @default.
• W4310673887 cites W2033585778 @default.
• W4310673887 cites W2046930642 @default.
• W4310673887 cites W2050737202 @default.
• W4310673887 cites W2051094694 @default.
• W4310673887 cites W2054776754 @default.
• W4310673887 cites W2054815188 @default.
• W4310673887 cites W2059321107 @default.
• W4310673887 cites W2061312317 @default.
• W4310673887 cites W2067756762 @default.
• W4310673887 cites W2098841271 @default.
• W4310673887 cites W2111445843 @default.
• W4310673887 cites W2115583388 @default.
• W4310673887 cites W2141158324 @default.
• W4310673887 cites W2143886321 @default.
• W4310673887 cites W2153976391 @default.
• W4310673887 cites W2159685920 @default.
• W4310673887 cites W2159906028 @default.
• W4310673887 cites W2275941545 @default.
• W4310673887 cites W2336746344 @default.
• W4310673887 cites W2441931074 @default.
• W4310673887 cites W2461777100 @default.
• W4310673887 cites W2516355868 @default.
• W4310673887 cites W2546627493 @default.
• W4310673887 cites W2563483938 @default.
• W4310673887 cites W2574322133 @default.
• W4310673887 cites W2619680342 @default.
• W4310673887 cites W2719355944 @default.
• W4310673887 cites W2751059225 @default.
• W4310673887 cites W2803148575 @default.
• W4310673887 cites W2884331139 @default.
• W4310673887 cites W2890339406 @default.
• W4310673887 cites W2921991970 @default.
• W4310673887 cites W2967974740 @default.
• W4310673887 cites W2979736764 @default.
• W4310673887 cites W2981518915 @default.
• W4310673887 cites W2992734068 @default.
• W4310673887 cites W3000770138 @default.
• W4310673887 cites W3003182193 @default.
• W4310673887 cites W3009160156 @default.
• W4310673887 cites W3031548538 @default.
• W4310673887 cites W3035448663 @default.
• W4310673887 cites W3049294089 @default.
• W4310673887 cites W3092204743 @default.
• W4310673887 cites W3093620139 @default.
• W4310673887 cites W3113251758 @default.
• W4310673887 cites W3134323342 @default.
• W4310673887 cites W3193698244 @default.
• W4310673887 cites W3197075976 @default.
• W4310673887 cites W3198434026 @default.
• W4310673887 cites W3208129759 @default.
• W4310673887 cites W3210190575 @default.
• W4310673887 cites W4220659089 @default.
• W4310673887 cites W4226397856 @default.
• W4310673887 cites W4234317413 @default.
• W4310673887 doi "https://doi.org/10.1016/j.cgh.2022.11.030" @default.
• W4310673887 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36470528" @default.
• W4310673887 hasPublicationYear "2023" @default.
• W4310673887 type Work @default.
• W4310673887 citedByCount "3" @default.
• W4310673887 countsByYear W43106738872023 @default.
• W4310673887 crossrefType "journal-article" @default.
• W4310673887 hasAuthorship W4310673887A5019403269 @default.
• W4310673887 hasAuthorship W4310673887A5029282864 @default.
• W4310673887 hasAuthorship W4310673887A5049602464 @default.
• W4310673887 hasAuthorship W4310673887A5050663021 @default.
• W4310673887 hasAuthorship W4310673887A5054615432 @default.
• W4310673887 hasAuthorship W4310673887A5070102732 @default.
• W4310673887 hasAuthorship W4310673887A5070183360 @default.
• W4310673887 hasAuthorship W4310673887A5082473440 @default.
• W4310673887 hasAuthorship W4310673887A5088567403 @default.
• W4310673887 hasAuthorship W4310673887A5089140297 @default.
• W4310673887 hasAuthorship W4310673887A5089562986 @default.
• W4310673887 hasBestOaLocation W43106738871 @default.
• W4310673887 hasConcept C126322002 @default.

• next